Monoclonal Antibodies Revolutionize Veterinary Health: Market on the Rise
Market Overview The global monoclonal antibodies in veterinary health market was valued at USD 785.71 million in 2022 and is expected to grow at a CAGR of 15.98% during the forecast period. This remarkable growth trajectory is largely driven by the rising adoption of advanced biologics in veterinary therapeutics, increasing prevalence of chronic diseases in companion and livestock animals, and heightened investments in animal healthcare research. Monoclonal antibodies (mAbs) are laboratory-produced molecules that can mimic the immune system's ability to fight off harmful pathogens. Originally developed for human medicine, mAbs have become a groundbreaking innovation in veterinary health as well. These biologics are being increasingly used to treat a variety of animal ailments, including cancer, autoimmune disorders, and infectious diseases, providing targeted, effective, and safe therapeutic options for animals. Key Market Growth Drivers One of the primary growth drivers in...